Founded in 1985, Innogenetics has been listed on the NASDAQ Europe since November 1996. Innogenetics is pursuing a challenging twofold growth strategy. The company is committed to becoming a worldwide leader in high value-added diagnostics (especially "theranostics") focusing on infectious diseases, neurodegeneration, and genetic testing. With its vertically integrated diagnostics activities, Innogenetics is leveraging its intellectual property, know-how and product offerings through strategic partnerships with leading in vitro diagnostic players such as Bayer, Roche, and Abbott. By running a profitable diagnostic business, Innogenetics can finance the development of new therapeutics. Innogenetics' has a wholly owned subsidiary XCELLentis. Innogenetics uses three distribution channels to market its diagnostic and theranostic products: its own affiliated companies located in Belgium (covering Benelux), France, Germany (covering Central Europe), Italy, Spain, and the USA; an international network of distributors and worldwide distribution agreements with strategic partners.